AMP-AD Biomarkers Project
The Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD) Biomarkers Project is a consortium of three NIA-supported Phase II/III secondary prevention trials (listed below) testing several anti-amyloid therapies. Through the AMP-AD partnership, imaging and fluid biomarker panels already included in these trials will be supplemented with tau PET imaging and novel fluid biomarkers.
The goal is to explore the utility of tau imaging and novel fluid biomarkers for tracking responsiveness to treatment and/or disease progression. Baseline data from the trials will be made broadly available through the Alzheimer Association’s GAAIN collaborative platform.
- International Alzheimer's Disease Research Portfolio
- Alzheimer’s Disease Neuroimaging Initiative
- Alzheimer’s Disease Cooperative Study
- NIH Network for Excellence in Neuroscience Clinical Trials
- Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Revue neurologique. 2013;169(10):10. www.ncbi.nlm.nih.gov/pubmed/24016464
- Reiman EM, Langbaum JBS, Fleisher AS, et al. Alzheimer’s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. Journal of Alzheimer’s Disease. 2011;26(Suppl 3):321-329. www.ncbi.nlm.nih.gov/pubmed/21971471
- Sperling RA, Rentz DM, Johnson KA, et al. The A4 Study: Stopping AD before symptoms begin? Science translational medicine. 2014;6(228):228fs13. www.ncbi.nlm.nih.gov/pubmed/24648338